Markets
Service dogs flying on Southwest.
These good bois (or girls) should still get to sit wherever they want (Getty Images)
HEDGE NO BETS

Southwest’s cost-cutting spree now includes a big gamble on oil prices

Fuel hedges are going off the menu at the airline.

Luke Kawa

As part of its cost-cutting spree, Southwest is ending a practice that has saved the company billions. 

Further plans to reduce expenses include “the discontinuation of our fuel hedging program, which eliminates additional fuel hedge premiums in the future,” CEO Bob Jordan said at JPMorgan’s Industrials Conference. “We’ll be opportunistic in unwinding our existing positions based on market conditions.”

The airline is pulling out all the stops to cut costs lately: unveiling a freeze on hiring and promotions in January, announcing the elimination of nearly 1,800 employees in February, and now this revelation in March.

Putting on and maintaining hedges costs money, and fuel is the second-largest operating expense for the airline after labor costs. But in the past, spending that money to hedge its exposure to fluctuations in fuel prices has been a way that Southwest ultimately kept costs down.

Bloomberg wrote that Southwest Airlines is “one of the few” airlines that maintained oil hedges following the financial crisis, which saved the company $3.5 billion in the 10 years through 2008. Its fuel costs have generally fluctuated much less than competitor American Airlines (which hasn’t hedged its exposure), and Southwest also outperformed its peers in the first half of 2022 when oil prices spiked following Russia’s invasion of Ukraine.

If fuel costs rise, the unwinding of these hedges could backfire in a big way for Southwest (and likely put upward pressure on ticket prices). And if fuel costs go down, well… I wouldn’t hold your breath waiting for Jordan & Co. to pass the savings along to you.

Southwest is certainly in a state of transition, if not upheaval, after a pressure campaign from activist Elliott Investment management led to a mass shakeup of its board last fall. Along with the recent bevy of cost-cutting measures, the company just announced the end of its “bags fly free” policy, which management expects will generate additional revenue going forward. Time flies — just six months ago, it said “bags fly free” would stay because cutting it would “drive down demand and far outweigh any revenue gains created.”

Add this to the list of signs that Southwest is trying to be just like every other airline.

More Markets

See all Markets
President Trump Delivers An Announcement From The Oval Office

Pharma largely unfazed as Greenland tariffs roil markets

Drugmakers, which have spent the past six months reaching tariff deals with Trump, seem to expect some immunity from a new batch of tariffs on European countries.

markets

POET Technologies nears multiyear high on strong call demand after flagship product wins award

POET Technologies is surging on heavy volumes and high call demand after announcing that it won a Product Innovation Award at China’s Infostone awards.

The honor went to the optical communications company’s flagship product, the Teralight, which uses light to move data between chips.

“Unveiled less than a year ago at the 2025 OFC Conference, POET Teralight has driven commercial interest in the Company because of its highly integrated design and complete optical system-on-chip architecture that simplifies module development,” per the press release.

This award may be the latest excuse to buy the stock, which is up over 40% year to date.

Call activity is elevated, with nearly 37,000 having changed hands as of 10:55 a.m. ET, well above the 20-day average of 28,030 for a full session. Shares are approaching their multi-year high of $9.41.

markets

Intel bucks market slump after Wall Street upgrades

While the market slid early Tuesday, Intel soared as the American chipmaker received a pair of upgrades:

  • HSBC analysts lifted their rating on the stock to “hold” — essentially “neutral” — from “reduce,” Wall Street-speak for “sell.” The analysts nearly doubled their price target for the shares to $50 from $26. (That’s essentially where the stock is currently trading.)

  • Seaport Global also boosted its rating to “buy” from “neutral,” with a $65 price target.

Improving demand for CPUs — Intel’s bread-and-butter processors — is behind HSBC’s newfound enthusiasm for the shares. Analysts at the bank wrote:

“We had been cautious on Intel mainly given overall uncertainty on customer pipeline and execution headwinds in their foundry business while the core business was also lacking visibility on growth drivers. However, we now turn more positive as we expect the traditional servers (DCAI) to get back on a growth trajectory. We expect there is an overwhelmingly increasing demand for server CPUs driven by rising agentic AI... While the stock has moved up 19% YTD (vs S&P 500 up 1%), we believe there is further [data center and AI group] upside still not fully priced in. Hence, we upgrade Intel from Reduce to Hold.”

HSBC seems to be slightly understating the extent of the gains for the stock so far in 2026, as its share price has risen nearly 30% since the end of last year. But the gains are even more impressive if you date them to the partial nationalization of the ailing American chip giant, which was announced on August 22. Almost a month later, Nvidia announced a strategic partnership with the company, giving it a massive shot in the arm. Since then the stock is up more than 90%.

markets

ImmunityBio surge continues on sign its drug may be approved to treat a broader range of bladder cancers

Once you start squeezing, you can’t put the toothpaste back in the tube.

Shares of ImmnuityBio are flying higher once again, up more than 30% in early trading Tuesday after having been down as much as 10% in the premarket. A little more than half an hour into the regular trading day, more than 46 million shares have changed hands, more than 3x the 20-day average for this point in the session.

Last week, we discussed how a number of positive press releases from the company touting the progress of its treatments helped send shares skyward, making the heavily shorted company a hot topic of discussion on the r/ShortSqueeze subreddit.

The positive press parade continues this morning, with ImmunityBio announcing that the FDA asked for more information about the ability of its ANKTIVA drug to treat a certain type of bladder cancer, though it doesn’t need to do any new clinical trials. Management said they would provide this information within 30 days.

Share are up nearly 200% over the past six sessions.

On Monday, the company published a podcast appearance by Dr. Patrick Soon-Shiong, founder, executive chairman, and global chief medical and technology officer, on “The Sean Spicer Show,” which was provocatively titled, “Is the FDA BLOCKING Life Saving Cancer Treatments?”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.